Registry for soft tissue reconstruction using Myriad™ devices

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study evaluates the safety and clinical outcomes of Myriad Matrix™ and Morcells™ in various soft tissue reconstruction procedures. Participants will be enrolled from multiple centers and will undergo surgical interventions where these devices are utilized as part of standard care. The study aims to gather data on a range of conditions, including abdominal wound dehiscence and necrotizing soft tissue infections, to assess the effectiveness of these treatments in real-world settings.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Willing and able to provide written informed consent and to comply with the requirements of Clinical Investigational Plan
* Male or female patients aged 18 years or above
* Patients where Matrix and/or Morcells were used as part of their soft tissue reconstruction procedure
* Subject that are willing and able to comply with all aspects of the treatment and evaluation schedule

Exclusion Criteria:

* Patients with known sensitivity to ovine (sheep) derived material
* Patients with full thickness ('third degree') burns
* Patients with wounds with uncontrolled clinical infection (CDC Contamination Grade=4)
* Any medical condition or serious intercurrent illness that, in the opinion of the investigator, may make it undesirable for the patient to participate in the study
* Patient is currently participating or has participated in another clinical study within past 30 days prior to enrollment
* Pregnant or lactating women
* Any subject who, at the discretion of the Investigator, is not suitable for inclusion in the study

Where it's running

• Asencion Sacred Heart
  Pensacola, Florida, United States Recruiting
• Northeast Georgia Medical Center, Inc.
  Gainesville, Georgia, United States Recruiting
• University Medical Center
  New Orleans, Louisiana, United States Recruiting
• Sinai Hospital of Baltimore
  Baltimore, Maryland, United States Recruiting
• Lancaster General Hospital
  Lancaster, Pennsylvania, United States Recruiting
• The Medical College of Wisconsin
  Milwaukee, Wisconsin, United States Recruiting

Study contacts

• Study coordinator: Barnaby May, PhD
• Email: barnaby.may@aroa.com
• Phone: +64 21 056 9995

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Electronic bidets after anal surgery vs water rinsing

  A small study tests whether using an electronic bidet after anal fistula or hemorrhoid surgery helps patients more than standard water rinsing.

  Recruiting Universitair Ziekenhuis Brussel · Brussels · NCT07874711

• BTK inhibitor remibrutinib in hidradenitis suppurativa shows how it works in adults

  This phase 1 trial tests whether remibrutinib can safely affect HS in adults with moderate to severe disease.

  Recruiting at 2 sites Phase 1 Novartis · San Diego, California and 1 other locations · NCT07855276

• Olatorepatide vs placebo for adults with moderate-to-severe hidradenitis suppurativa who are overweight

  This study tests whether olatorepatide can help people with hidradenitis suppurativa who are overweight or obese.

  Recruiting Phase 2 Regeneron Pharmaceuticals · The Bronx, New York · NCT07830329

• Artificial Intelligence-Supported Pressure Injury Prevention in ICU Patients

  This study tests PRESS AI, a mobile app, to help nurses prevent and manage pressure injuries in adult ICU patients by guiding risk and wound assessment and care decisions.

  Recruiting Ankara Yildirim Beyazıt University · Ankara, Ankara · NCT07779395

• Remibrutinib extension study for adults with moderate to severe hidradenitis suppurativa

  This extension study tests whether continuing remibrutinib is safe and helps skin symptoms in adults who completed prior HS trials.

  Recruiting at 61 sites Phase 3 Novartis · Birmingham, Alabama and 60 other locations · NCT07665437

• LAD328 in adults with hidradenitis suppurativa

  This study tests whether LAD328 works better than placebo for adults with moderate-to-severe hidradenitis suppurativa.

  Recruiting Phase 2 Almirall, S.A. · Warsaw, Masovian Voivodeship · NCT07547813

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.